Loading...
Loading...
ALGS| Name | Value |
|---|---|
| Revenues | 3.2M |
| Cost of Revenue | 0.7M |
| Gross Profit | 2.6M |
| Operating Expense | 22.3M |
| Operating I/L | -19.1M |
| Other Income/Expense | 1.1M |
| Interest Income | 1.0M |
| Pretax | -18.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -18.0M |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for viral and liver diseases. The company's lead drug candidates, including ALG-010133 and ALG-000184, are in clinical trials for the treatment of chronic hepatitis B (CHB). Additionally, Aligos is developing other promising drug candidates such as ALG-020572 and ALG-055009 for the treatment of hepatitis B and non-alcoholic steatohepatitis (NASH), respectively. The company has also entered into strategic collaborations to develop and commercialize products targeting hepatitis B virus and coronavirus protease inhibitors, demonstrating a strong focus on advancing its pipeline and generating revenue through partnerships and product commercialization.
